Rx Pharmaceuticals

Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg

Bausch & Lomb Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg is the world's first intravitreal drug implant for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
















Uveitis is one of the leading causes of blindness for middle-aged people in the Western world. It is estimated to cause 10% to 15% of all cases of total blindness in the United States.¹

Retisert® represents a dramatic advance in the management of chronic noninfectious uveitis affecting the posterior segment of the eye. Now, for the first time, retina and uveitis specialists have the means to provide consistent long-term delivery of a corticosteroid agent, fluocinolone acetonide, precisely where it's needed.

Bausch & Lomb's patented drug-delivery microtechnology in Retisert consists of a tiny drug reservoir designed to deliver sustained levels of the well-known anti-inflammatory corticosteroid, fluocinolone acetonide, for approximately two-and-a-half years (30 months) directly to the back of the eye.

Important Safety Information

Surgical placement of Retisert is contraindicated in active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in active bacterial, mycobacterial or fungal infections of the eye. Late onset endophthalmitis has been observed, often related to the integrity of the surgical wound site.

Prolonged use of corticosteroids may result in elevated IOP and/or glaucoma, as well as increase the hazard of secondary ocular infections (bacterial, fungal and viral).

Based on clinical trials with Retisert, within 3-years post implantation, approximately 77% of patients will require IOP lowering medications to control intraocular pressure and 37% of patients will require filtering procedures to control intraocular pressure. During the 3-year post-implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery.

The most frequently reported ocular adverse events in clinical trials with Retisert were cataract, increased intraocular pressure, procedural complication, and eye pain. These events occurred in approximately 50 –90% of patients. Procedural complications include post-op complication, post-op wound complication, post-op wound site erythema, and wound dehiscence.

Please see full prescribing information for Retisert.

Important Information

For more information about Retisert®, please contact Customer Service at (800) 323-0000.
Click here for Retisert Product Fact Sheet.

To access our Reimbursement Support Program, please contact (866) 250-2974.Click here to download a blank reimbursement support worksheet.

References: 1. Suttorp-Schulten MSA, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Opthalmol. 1996;80:844-848

Increase Type Size

Decrease Type Size